Cystic Fibrosis
Since the discovery of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene in 1989, more than 2000 mutations have been described in patients with Cystic Fibrosis. Many of these mutations are rare, having been identified in only one patient and/or family. It is common practise to screen for the most common CFTR mutations first, as routine detection of all mutations is not cost-effective for many molecular genetics laboratories. Elucigene Diagnostics have produced a suite of diagnostic products targeting the most common CFTR mutations, providing maximum clinical coverage at a competitive price.
Kit Name | Description | Platform | Catalogue Code | |
CFEU2v1 | Detects the 50 most common mutations in the European population. | Genetic Analyser | CF2EUB2 | More Information |
CF4v2 | Detects the 4 most common mutations in the European population. | Genetic Analyser | CF4HTB1 | More Information |
CF30v2 | Detects the 29 most common mutations in the French population. | Gel Based | CF030B1 | More Information |
CF-DE | Detects the 31 mutations outlined by the G-BA for newborn screening in Germany. | Genetic Analyser | CF1DEB2 | More Information |
CF Italia | Bolt on to CFEU2v1 to increase the mutation coverage for the Italian population. | Genetic Analyser | CFITAB1 | More Information |
CF Iberian | Bolt on to CFEU2v1 to increase the mutation coverage for the Iberian population. | Genetic Analyser | CFIBNB1 | More Information |
CF-UK | Bolt on to CFEU2v1 to increase the mutation coverage for the British population. | Genetic Analyser | CF1UKB1 | More Information |